Throughout 2024, China’s patent litigation remained active. The IP Tribunal of the Supreme People’s Court (SPC) has issued decisions providing further guidance on damages calculation in the SEP/FRAND and life sciences sectors. The SPC has also leveraged pertinent decisions outlining the liabilities of patentees acting in bad faith. These decisions showcase the current juridical practice of Chinese courts relating to the said issues, yet it remains to be seen how the jurisprudence will evolve in 2025.